Exclusive Summary

• **First-in-Class Oral Weekly Dosing**: Utilizes Ranipill™ technology to achieve 80-160% bioavailability via oral delivery, enabling once-weekly dosing that rivals injectable efficacy.
• **Differentiated GLP-1/GLP-2 Mechanism**: Uniquely addresses muscle loss associated with weight loss drugs; the GLP-2 component promotes protein absorption and preserves lean mass while improving gut health.
• **Strong Phase 1 Clinical Proof-of-Concept**: Demonstrated rapid efficacy with 4.8% average weight loss (max 8.7%) in just 5 weeks, accompanied by a favorable safety profile and low GI side effects.

Asset Materials

Contact Us for Full Materials